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CC BY-NC-ND license (http://creativeAbstract We evaluated the isolation and quantitation of Clostridium difficile from aqueous
and fecal samples utilizing ChromID CDIF and cycloserine, cefoxitin, and fructose-containing
agar with horse blood and taurocholate media. Growth was similar between the two. ChromID
CDIF provided enhanced isolation and required no ethanol pretreatment to inhibit normal
flora. ChromID CDIF also improved turn-around time, requiring only 24 hours’ incubation.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).The prevalence of Clostridium difficile infections (CDI) has
increased dramatically over the past decade.1 The methods
used to identify the presence of C. difficile in the clinical
microbiology laboratory have also increased. The gold
standard continues to be culture on cycloserine, cefoxitin,
and fructose-containing agar (CCFA) followed by cytotoxin
detection. Other diagnostic testing mechanisms includeAnti-Infective Research and
eymour Street, Hartford, CT
health.org (D.P. Nicolau).
.05.012
Society of Microbiology. Publishe
commons.org/licenses/by-nc-nd/enzyme immunoassay and polymerase chain reaction (PCR)
testing. While each diagnostic has its pros and cons, a full
review can be found in the Society for Healthcare Epide-
miology of America/Infectious Diseases Society of America
C. difficile guidelines.2 ChromID CDIF, a new chromogenic
agar developed by bioMe´rieux (Marcy l’Etoile, France) has
provided another way to culture and identify C. difficile.
Previous studies utilizing this media have identified
enhanced recovery of C. difficile from fecal samples on
ChromID CDIF compared with other media types.3,4 A
recent publication by Luk et al5 also demonstrated a
beneficial cost reduction using chromogenic agar and ad by Elsevier Taiwan LLC. This is an open access article under the
4.0/).
Figure 1. Comparison of Clostridium difficile densities in
fecal samples from patients with C. difficile infections.
446 S.T. Housman et al.slight increase in identification of positive specimens (9%)
compared with real-time PCR. This was in exchange for an
increase in turn-around time of 1 day. While the isolation of
C. difficile using different plates has been extensively
described, the quantitation of C. difficile within the stool
of infected patients has not. As such, we aimed to quanti-
tatively and qualitatively assess the performance of Chro-
mID CDIF and CCFA with horse blood and taurocholate
(CCFA-HT) media utilizing an aqueous matrix and stool
samples from patients diagnosed with CDI over a range of
bacterial densities.
ChromID CDIF agar was purchased from bioMe´rieux as
commercially prepared plates. CCFA-HT plates were ob-
tained from Anaerobe Systems (Morgan Hill, CA, USA) as
commercially prepared, prereduced, individually packaged
plates. All plates were removed from the packaging and
transferred to an anaerobic jar within 30 minutes following
sample plating.
To evaluate the growth of C. difficile on these selective
media, C. difficile ATCC 9689 strain was transferred from a
frozen stock onto anaerobic blood agar plates and grown
anaerobically overnight at 37C. A second subculture was
performed and incubated similarly. From the second sub-
culture, a 0.5e1 McFarland standard bacterial suspension
was prepared in phosphate-buffered saline (PBS). Serial 10-
fold dilutions were plated onto ChromID CDIF agar and
CCFA-HT agar. This procedure was repeated seven inde-
pendent times. The ChromID CDIF and CCFA-HT plates were
incubated under anaerobic at 37C conditions for 24 hours
and 48 hours, respectively, before enumeration of colony
counts.
Quantitation of C. difficile from patients with
laboratory-confirmed CDI by PCR testing was then per-
formed after obtaining informed consent. Fecal samples
from patients diagnosed with CDI were obtained from the
microbiology laboratory or directly from the patient prior
to, during, or after receiving treatment. Within 12 hours of
the bowel movement, the stool sample was obtained and
processed. A sufficient amount of the stool sample
(0.5e1 g) was weighed and an equal volume of PBS added.
This primary emulsion was mixed thoroughly. To obtain
spores, an aliquot (0.5e1 g) was taken from the primary
emulsion, weighed, and diluted with an equal part of 95%
EtOH (POST sample) and placed on an orbital shaker for 60
minutes. Another aliquot was taken from the primary
emulsion, weighed, and diluted with an equal part of PBS
(PRE sample). This sample included vegetative cells of C.
difficile as well as spores. The POST and PRE samples were
a final 1:4 dilution of the original patient fecal sample.
Once the samples were diluted to a final 1:4 dilution, serial
10-fold dilutions of each sample were plated onto ChromID
CDIF and CCFA-HT plates in duplicate. The plates were
incubated as described above. Vegetative cells were
calculated by taking the total colony-forming units (CFU)/g
from the PRE plates and subtracting the total CFU/g from
the POST plates. This process was repeated for 46 individ-
ual samples.
In the aqueous matrix, the bacterial density on ChromID
CDIF read at 24 hours was similar to that on CCFA-HT read
at 48 hours, 6.66  0.62 log10CFU/mL and 6.13  1.23
log10CFU/mL (p Z 0.124), respectively. The bacterial
density in fecal samples from patients with CDI on ChromIDCDIF versus CCFA-HT is depicted in Figure 1. Recovery by
quantitative methods was similar albeit slightly lower on
ChromID CDIF compared with CCFA-HT media. C. difficile
growth was present on 23/46 (50%) of samples for both
CCFA-HT media and ChromID CDIF media following EtOH
exposure (POST). From the PRE samples, C. difficile was
cultured from 15/46 samples (33%) on CCFA-HT agar and
27/46 samples (59%) on ChromID CDIF media. Fourteen PRE
samples had normal flora on the CCFA-HT media but not on
the ChromID CDIF media, inhibiting enumeration and
isolation of C. difficile. Three samples with the greatest
differences were repeated in duplicate. Variability among
individual samples was present but we observed similar
results when enumeration was done an additional two
times.
The use of chromogenic media to identify specific spe-
cies in a clinical setting has provided relatively quick
detection and quantitation of infecting pathogens. In the
current study, we systematically studied the ability to
quantitate C. difficile in a saline solution as well as isolate
and quantitate the organism from stool utilizing the Chro-
mID CDIF media compared with the gold standard, CCFA-HT
media. In PBS, similar bacterial densities were present on
the two types of media indicating that the media provides
sufficient growth. Utilizing samples from multiple patients,
ChromID CDIF media was able to isolate and quantitate C.
difficile from more samples than with CCFA-HT. This was
accomplished with a reduced incubation period and
without the need for EtOH pretreatment, reducing both
preparation time and turn-around time. This reduced turn-
around time was also highlighted by Carson and col-
leagues.6 Further, the authors semiquantitatively assessed
C. difficile growth in fecal samples utilizing isolates present
in the first, second, third, and/or fourth quadrant. The
current study was able to expand on the initial work of
Carson et al6 and perform a quantitative assessment uti-
lizing absolute log10CFU/g of stool concentrations and
compare ChromID CDIF with CCFA-HT media.
It is important to note that when considering duplicate
quantitative cultures for both media, variability in bacterial
densities were observed. As the variability was noted on
Isolation on ChromID CDIF vs. CCFA-HT 447both types of media, it is hypothesized this is due in part to
the minimal diluting done to maintain sufficient bacterial
counts above the lower limit of detection and the consis-
tency of the sample. Stool samples ranged from Bristol stool
scale 3e7 and we did not observe any correlation between
variability and a lower or higher Bristol stool scale.
The ability to isolate and quantify C. difficile in fecal
matter from patients using ChromID CDIF has important
clinical, economic, and research implications. As microbi-
ology laboratories and health systems continue to look for
the most efficient use of new technologies, ChromID CDIF is
able to reduce normal flora that the CCFA-HT media does
not, allowing effective detection and quantitation of C.
difficile in resource limited environments. The quantitation
methods described herein provide a framework to conduct
research to better understand the bacterial concentration
of C. difficile within stool samples of patients with CDI.
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